Welcome to our dedicated page for AN2 Therapeutics news (Ticker: ANTX), a resource for investors and traders seeking the latest updates and insights on AN2 Therapeutics stock.
AN2 Therapeutics, Inc. (Nasdaq: ANTX) is a clinical-stage biopharmaceutical company based in California focusing on developing innovative treatments for rare, chronic, and serious infectious diseases. The company’s mission is to harness modern biomedical expertise to create transformative medicines for patients globally. AN2’s leading drug candidate, epetraborole, targets non-tuberculous mycobacterial (NTM) lung disease, an often fatal and progressive bacterial infection.
Currently, AN2 is conducting a pivotal Phase 2/3 clinical trial of epetraborole for treatment-refractory Mycobacterium avium complex (MAC) lung disease. The trial, which operates across over 100 clinical sites in the U.S., Japan, South Korea, and Australia, aims to provide a new oral treatment option for patients with limited alternatives. The company recently announced the voluntary pause of Phase 3 enrollment following an analysis of Phase 2 data, allowing time for more in-depth review and potential modifications based on feedback from the FDA.
AN2 Therapeutics reported robust financial health with cash and investments of $118.1 million as of March 31, 2024, ensuring the continuation of their research and development endeavors. Besides epetraborole, AN2 is also progressing in other areas such as Chagas disease and tuberculosis, supported by grants from the Bill & Melinda Gates Foundation and collaborations with esteemed institutions like the University of Georgia.
The company's dedication to addressing unmet medical needs is further demonstrated through its boron chemistry platform, which aims to discover novel therapies for global health challenges. With ongoing clinical trials and a solid financial foundation, AN2 Therapeutics positions itself as a key player in the fight against infectious diseases.
AN2 Therapeutics, Inc. (Nasdaq: ANTX) recently reported its financial results for 2022, marking a transformative year as the company transitioned to public status. The pivotal Phase 2/3 trial for epetraborole, targeting treatment-refractory Mycobacterium avium complex (MAC) lung disease, is currently progressing with nearly 60 clinical sites globally, including newly opened sites in Japan, South Korea, and Australia. The company received significant funding of up to $17.8M for developing epetraborole against melioidosis. In 2022, R&D expenses increased to $29.5M, while the net loss reached $41M. AN2's cash reserves are projected to last through mid-2024, supporting ongoing clinical efforts.
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company, announced its participation in two investor conferences in March 2023. The first is the Cowen 43rd Annual Health Care Conference in Boston, where CEO Eric Easom will join an Infectious Disease panel on March 7. The second event is the Oppenheimer 33rd Annual Healthcare Conference, with Easom providing a corporate overview on March 14. Webcasts will be accessible on the AN2 Therapeutics website, with archived replays available for 30 days post-event. Their lead candidate, epetraborole, is being studied for NTM lung disease.
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company, announced that CEO Eric Easom will present at the SVB Securities Global Biopharma Conference on February 14, 2023, at 5:00 p.m. ET. This virtual event focuses on the company's efforts to develop treatments for serious infectious diseases, particularly their lead candidate epetraborole, designed to treat NTM lung disease. A webcast of the presentation will be available in the Investors section of their website, with archived access for 30 days post-event.
AN2 Therapeutics, Inc. (ANTX) announced ongoing U.S. enrollment for its pivotal Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease, planning to include Japanese patients. The company has secured a $17.8 million contract from NIAID to develop epetraborole for acute systemic melioidosis. Financially, R&D expenses rose due to trial activities and personnel increases, while G&A costs also increased. As of September 30, 2022, AN2 had $106.4 million in cash, providing a runway through mid-2024.
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical firm specializing in treatments for severe infectious diseases, announced participation in two investor conferences in November 2022. The Stifel 2022 Healthcare Conference will take place from November 15-17 in New York, where CEO Eric Easom will present on November 16 at 9:10 a.m. ET. Additionally, Easom will join a fireside chat at the 5th Annual Evercore ISI HealthConX Conference on November 30 at 2:15 p.m. ET. Webcasts for both events will be accessible on the company’s website.
AN2 Therapeutics, Inc. (Nasdaq: ANTX) announced ongoing enrollment in a pivotal Phase 2/3 trial for epetraborole, targeting treatment-refractory Mycobacterium avium complex (MAC) lung disease. The company also presented new findings at the IDWeek 2022 Conference, which took place from October 19-24, 2022. Notable presentations included an oral talk on epetraborole's role as an innovative oral antibiotic and several posters detailing pharmacokinetic studies and dose-response analyses. These efforts emphasize the potential of epetraborole as a critical treatment option for patients with NTM lung disease.
AN2 Therapeutics, Inc. (Nasdaq: ANTX) announced progress in its epetraborole development for treatment-refractory Mycobacterium avium complex (MAC) lung disease. Data from a recent Phase 1 study in Japan supports a 500 mg daily dose. The clinical development strategy prioritizes Japan and the U.S., highlighting their high MAC lung disease prevalence. Additionally, the European Commission granted orphan medicinal product designation for epetraborole in NTM lung disease, providing market exclusivity and support for further development.
AN2 Therapeutics announced a $17.8 million contract from the NIAID to advance epetraborole for treating acute systemic melioidosis, with a base period of $4.3 million. This funding supports preclinical and Phase 1 studies, aiming for a pivotal Phase 2/3 trial. The initiative addresses a significant global health need and potential U.S. biothreat, leveraging existing efforts against Nontuberculous Mycobacterial (NTM) lung disease.
Melioidosis, caused by Burkholderia pseudomallei, poses severe health risks, especially in tropical regions, with a mortality rate of 20-40% even with treatment.
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company, announced that Eric Easom, President and CEO, will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The on-demand presentation will be available starting September 12 at 7:00 A.M. E.T. Investors can access the webcast on the AN2 Therapeutics website, with an archived replay available for 30 days.
AN2 Therapeutics (ANTX) reported significant progress in its epetraborole clinical program, initiating a pivotal Phase 2/3 trial for treatment-refractory MAC lung disease in the U.S. and completing a Phase 1 safety study in Japan. The company gained alignment with the PMDA on the use of a microbiological primary endpoint for potential registration in Japan and plans to include Japanese patients in the ongoing trial. Financially, R&D expenses rose to $6.7 million from $3.9 million year-over-year, while G&A expenses increased to $3.6 million from $0.9 million. Cash reserves stood at $115.8 million, sufficient to fund operations through mid-2024.
FAQ
What is the current stock price of AN2 Therapeutics (ANTX)?
What is the market cap of AN2 Therapeutics (ANTX)?
What does AN2 Therapeutics, Inc. specialize in?
What is the main product candidate of AN2 Therapeutics?
What is the current status of epetraborole’s clinical trials?
Has AN2 Therapeutics halted any part of their clinical trials?
What recent financial updates were provided by AN2 Therapeutics?
Who are some of the major collaborators and supporters of AN2 Therapeutics' research?
What other diseases is AN2 Therapeutics targeting apart from NTM lung disease?
When is the Phase 2 topline data for epetraborole expected to be announced?
What is the vision of AN2 Therapeutics?
Where can I find more information about AN2 Therapeutics?
